FILTER

FILTERED INTERVIEW RESULTS

Donna LaVoie

PRESIDENT AND CEO, LAVOIEHEALTHSCIENCE
"Companies should be ready to address hostile short-selling and unsolicited takeover bids, develop rapid responses to special meetings and activist demands, and vigorously engage with institutional shareholders, proxy advisory firms, and potential regulators."

Daniel Prince

CEO, PRINCE STERILIZATION SERVICES
"The expansion will allow Prince to more than double its headcount, increase manufacturing capacity, and offer additional ready-to-use products and sterilization services to the market."

Tom Sellig

CEO, ADARE PHARMA SOLUTIONS
"For every challenge, we have a set of tools we can leverage to create optimized solutions beyond taste masking."

Louis Kassa

PRESIDENT AND CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"I hope to continue seeing companies coming from across the country contributing to the significant growth of the greater Philadelphia area in life sciences."

Denis Dufrane

CO-FOUNDER AND CEO, NOVADIP
"I believe 2023 and 2024 will be key for Novadip. We have already closed two trials in the autologous program. We are now in Phase 1/2 trials for CPT in young patients, both in the US and in Europe."

Jeff Butler

PRESIDENT, AMPAC FINE CHEMICALS
"AFC’s core technology differentiators include energetic chemistry, high potency manufacturing, and extensive chromatographic separation capabilities."

Tyrone Brewer

PRESIDENT, US ONCOLOGY, JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
"I am excited about Janssen’s aspirational vision to eliminate cancer. With targeted therapies and immunotherapies, cancer treatment can be more effective and less toxic, enabling individuals to manage their disease while also maintaining their quality of life."

Joe Panetta

PRESIDENT AND CEO, BIOCOM CALIFORNIA
"The lifecycle of new product introduction into the market will now be shorter, as companies have fewer years to recover revenue as a result of the IRA."

Andrea Confetti & Roberto Fanelli

EXCLUSIVE SYNTHESIS BUSINESS UNIT LEADER (AC) & CATALOGUE APIS BU DEPUTY MANAGER (RF), DIPHARMA FRANCIS
RF: "Our experience in developing proprietary chemical processes and alternative solutions to support the generic API industry has been instrumental in rapidly expanding our CDMO activities."

Daniel Palmacci

PRESIDENT, CELL & GENE DIVISION, LONZA
"We want to give patients the best access to the amazing technology and treatments being developed by cell and gene therapy innovators. This is the modality with the greatest potential in the healthcare industry today."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

Mongolia Mining 2024 - Digital Interactive

Investors once came to Mongolia for its geology yet stumbled upon its legislative framework. How competitive Mongolia has become today, we will leave our readers to judge, hoping that this report provides them with the resources to make an informed assessment.

PARTNER EVENTS